FDA approves Spark's gene therapy for rare blindness pioneered at CHOP

Posted on Tuesday, Dec 19, 2017
The Food and Drug Administration approves Philadelphia drug maker Spark Therapeutics' first ever gene therapy for a genetic disease, developed at Children's Hospital of Philadelphia.